Kymera Therapeutics Inc (KYMR) FinancialsKYMRKymera Therapeutics Inc

Evaluating the bottom line, Kymera Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -116.32%, while the net margin is -94.17%. These profitability ratios, combined with a Return on Equity (ROE) of -24.15%, provide a clear picture of how effectively KYMR converts its operational activities into shareholder value.

In the context of the broader market, KYMR competes directly with industry leaders such as TWST and KRYS. With a market capitalization of $9.55B, it holds a significant position in the sector. When comparing efficiency, KYMR's gross margin of 100.00% stands against TWST's 52.76% and KRYS's 94.60%. Such benchmarking helps identify whether Kymera Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Kymera has shown a gross margin of 100% across recent quarters, indicating strong revenue generation relative to costs, despite negative net income figures. The current ratio is strong at 10.34, suggesting good short-term financial health.